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BY-NC-ND license (http://creativecomBackground/purpose: This study aimed to evaluate the outcomes of chronic hepatitis B
patients with cirrhosis who received long-term nucleos(t)ide analog therapy.
Methods: A total of 546 consecutive cirrhotic patients treated with entecavir (n Z 359), tel-
bivudine (nZ 104), or tenofovir (nZ 83) for chronic hepatitis B were enrolled. The incidence
of hepatocellular carcinoma (HCC) and overall survival were evaluated.
Results: During a median follow-up of 39 months, 56 (10.3%) patients developed HCC and 14
(2.6%) patients died. These outcomes were not associated with different antiviral use. Cox pro-
portional hazard analysis showed that old age (60 years) [hazard ratio (HR), 1.74; pZ 0.046],
statin use (HR, 2.42; p Z 0.017), low platelet count (<100,000/mL; HR, 2.00; p Z 0.039), and
variceal bleeding history (HR, 5.12; p < 0.001) were independent factors for HCC development.
With regard to survival, ChildePugh B/C (HR, 3.78; pZ 0.039) and low platelet count (<105/mL;
HR, 7.82; pZ 0.049) were independent factors. The estimated glomerular filtration rate signif-
icantly increased in patients receiving telbivudine (pZ 0.047), but decreased in those receiving
tenofovir (p < 0.001) at Year 2. Tenofovir use (HR, 1.98; pZ 0.005) was one of the independent
factors associated with the progression of chronic kidney disease stage.
Conclusion: Long-term nucleos(t)ide analog therapy does not guarantee against the HCC devel-
opment and mortality in chronic hepatitis B-related cirrhotic patients. Careful HCC surveillance
is necessary in patients with old age, statin use, low platelet count, and variceal bleeding his-
tory.
Copyright ª 2016, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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Chronic hepatitis B (CHB) is one of the most common in-
fectious diseases, affecting approximately 370 million
people worldwide.1 Long-term complications of infection
include cirrhosis and hepatocellular carcinoma (HCC),
which together cause over 700,000 deaths annually.2,3
Among patients with active viral replication, cirrhosis will
develop in 15e20% within 5 years.4 In cirrhotic patients, the
5-year probability of decompensation is 15e20%. Once pa-
tients progress to develop decompensated cirrhosis, the
prognosis is poor, with a 5-year survival rate of only 14%.4
Several natural history studies have shown that high
serum hepatitis B virus (HBV) DNA levels are associated with
an increased risk of disease progression.5,6 Continuous
treatment with nucleos(t)ide analogs (NUCs) have been
reported to delay clinical progression in CHB patients with
and without cirrhosis, by significantly reducing the inci-
dence of hepatic decompensation and the risk of HCC.7e9 In
a meta-analysis that pooled five studies and a total of 2289
CHB patients, the risk of HCC was reduced by 78% among
those receiving NUC therapy relative to controls who did
not receive NUCs.10 However, some literatures have re-
ported no beneficial effects of NUCs to reduce HCC risk
among CHB patients.9,11
Lamivudine (LAM) is the first effective oral HBV repli-
cation suppressive agent and has been shown to decrease
progression of the disease in patients with CHB and cirrhosis
or advanced fibrosis.7 Moreover, the emergence of YMDD
mutations reduced the benefit of LAM but did not negate
it.7,12 Telbivudine (LdT) is another NUC with greater HBV
DNA suppression and less resistance than LAM.13 Entecavir
(ETV) and tenofovir disoproxil fumarate (TDF) are newer,
potent, rapidly acting oral NUCs that have been shown to
be highly effective in suppressing HBV replication.14,15
Until now, the effectiveness of these newer NUCs in
preventing disease progression and their safety profiles on
long-term use in CHB patients with cirrhosis remain un-
known. Thus, we conducted this study to determine the
efficacy of LdT, ETV, or TDF in real-world clinical setting of
disease progression, defined by developing HCC or death
related to liver disease among CHB patients with cirrhosis.
Patients and methods
Patients
From January 2007 to December 2013, consecutive cirrhotic
patients treatedwith ETV, LdT, or TDF for CHBwere recruited
in a singlemedical center. All patients had positive hepatitis B
surface antigen (HBsAg) for more than 6 months and serum
HBV DNA  2000 international units (IU)/mL at baseline. Pa-
tients who had coinfection with human immunodeficiency
virus, hepatitis A virus, hepatitis C virus, hepatitis D virus, or
hepatitis E virus by serological assays or thosewho developed
HCC by imaging studies before the start or within half a year
of treatment were excluded. Patients who had evidence of
drug-induced injury or alcohol abuse, definedas consumption
of alcohol >50 g/d, were also excluded.16
Cirrhosis was either histopathologically or clinically
diagnosed. Clinical diagnosis was based on the ultrasoundPlease cite this article in press as: Tsai M-C, et al., Long-term outcom
analogs, Journal of the Formosan Medical Association (2016), http://dfindings of coarse liver parenchyma with nodularity and
small liver size, and the presence of features of portal
hypertension.17 In the absence of histological proof, reim-
bursement of NUCs for the indication of CHB-related
cirrhosis required the presence of splenomegaly or esoph-
agogastric varices in addition to ultrasonographic diag-
nosis.18 Certain drugs, including statins, antiplatelet
agents, and metformin, which might affect the risk of HCC,
were analyzed. Exposure to these drugs was defined as use
of more than 3 months during the observation period. We
collected the date of prescription, daily dose, and number
of days supplied. The defined daily doses (DDDs) recom-
mended by the World Health Organization19 were used to
quantify usage of statins. Cumulative DDD was estimated as
the sum of dispensed DDDs of any statins (namely simva-
statin, rosuvastatin, pitavastatin, fluvastatin, or atorvas-
tatin) from the starting date of antiviral treatment.
Treatment and follow-up
Patients were antiviral treatment naı¨ve and received
600 mg of LdT, 0.5 mg of ETV, or 300 mg of TDF once daily.
For those who developed on-treatment virological break-
through, adefovir at a daily dose of 10 mg was added. Oc-
casionally, the dosage might vary according to individual
conditions such as renal impairment.
All patients were followed up every 3 months or more
frequently, as required.20 Routine follow-up studies
included clinical assessment, conventional biochemical
tests, and HCC screening using serum alpha-fetoprotein and
ultrasonography. A new space-occupying lesion detected or
suspected at the time of ultrasonography was further
examined with computed tomography or fine needle aspi-
ration biopsy. The diagnosis of HCC was compatible with
the guidelines of the American Association for the Study of
Liver Disease.21,22 The starting date of follow-up of each
patient began at the initiation of antiviral treatment. The
end of follow-up was the date of diagnosis of HCC, date of
death, or closing date of the study, June 30, 2014. This
study protocol conformed to the ethical guidelines of the
1975 Declaration of Helsinki and was approved by the
ethical committees of Chang Gung Memorial Hospital (IRB
no. 103-6631B).
Laboratory assays
HBsAg, hepatitis B e antigen, antihepatitis C virus antibody,
and antihepatitis D virus antibody were assessed using
commercially available kits (HBsAg enzyme immunoassay,
Abbott, North Chicago, IL, USA; hepatitis B e antigen
enzyme immunoassay, Abbott; antihepatitis C virus enzyme
immunoassay 3.0, Abbott; and antihepatitis D virus radio-
immunoassay, Abbott). Serum HBV DNA levels were
analyzed using the COBAS AmpliPrep-COBAS TaqMan HBV
test (CAP-CTM; Roche Molecular Systems, Inc., Branchburg,
NJ, USA), with a lower detection limit of 70 copies/mL. HBV
genotypes were determined using restriction fragment
length polymorphism on the surface-gene sequence,
amplified by polymerase chain reaction with nested
primers, as described previously.23 HBsAg titers were
quantified by the Elecsys HBsAg II Quant reagent kits (Rochees of hepatitis B virus-related cirrhosis treated with nucleos(t)ide
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facturer’s instructions.Statistical analysis
Continuous data are expressed as mean  standard devia-
tion, and categorical data are expressed as numbers (per-
centage). Comparisons of differences in the categorical
data between groups were performed using the chi-square
test or Fisher exact test. Distributions of continuous vari-
ables were analyzed by the ManneWhitney U test or one-
way analysis of variance test with the least significant dif-
ference post hoc correction between groups where appro-
priate. Paired t test was performed to compare the
estimated glomerular filtration rate (GFR) in serial
measurements.
Cumulative incidences of HCC development, overall
mortality, and progression of chronic kidney disease (CKD)
stage were analyzed by the KaplaneMeier method with aTable 1 Baseline characteristics of the study population.
Total (n Z 546) Entecavir (n Z 3
Age (y) 57.7  11.1 57.8  10.8a
Male gender 401 (73) 258 (72)
Body mass index (kg/m2) 25.0  3.6 25.0  3.4
Diabetes mellitus 112 (21) 70 (19)
Metformin use 63 (12) 37 (10)
Hypertension 127 (23) 79 (22)
Statin use 34 (6) 22 (6)
Cumulative DDD of statin 922  693 939  834
Antiplatelet agents use 25 (5) 14 (4)
HBV DNA (log10 copies/mL) 6.3  1.3 6.3  1.3c
HBV genotype (B/C)d 275/221 176/147
HBsAg titere (IU/mL) 2864  5367 2891  5438
HBeAg positive 118 (22) 84 (23)
AST (U/L) 91  133 96  142
ALT (U/L) 107  169 111  172
ChildePugh class B or C 81 (15) 59 (16)
Total bilirubin (mg/dL) 1.7  3.4 1.9  3.8
Albumin (g/dL) 3.8  0.5 3.8  0.5a
Creatinine (mg/dL) 1.1  1.4 1.1  1.6
CKD stage (I/II/III/IV/V) 208/194/41/11 128/123/28/8
Estimated GFR (MDRD) 88  28 87  28
Alpha-fetoprotein (ng/mL) 35  150 31  103a
Platelet (103/mL) 133  57 131  57a
MELD score 9.2  3.7 9.4  3.9a
Ascites 53 (10) 36 (10)
Variceal bleeding history 23 (4) 12 (3)c
Follow-up time (mo) 39.5  17.8 43.8  18.2a,c
Data are expressed as mean  standard deviation or n (%).
ALT Z alanine aminotransferase; AST Z aspartate aminotransferas
GFR Z glomerular filtration rate; HBeAg Z hepatitis B e antigen;
LSD Z least significant difference; MDRDZ modification of diet in re
disease.
a Significant differences entecavir and tenofovir.
b Significant differences between telbivudine and tenofovir with LS
c Significant differences between entecavir and telbivudine.
d Available in 496 patients.
e Available in 222 patients.
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increase of at least one stage in the follow-up. Univariate
and multivariate analyses were carried out to identify in-
dependent factors using the Cox proportional hazard
regression models. All analyses were carried out using SPSS
software version 15.0 (SPSS, Inc., Chicago, IL, USA). All
statistical tests were two tailed, and a p value < 0.05 was
considered statistically significant.Results
Baseline characteristics
A total of 546 CHB-related cirrhotic patients receiving ETV
(n Z 359), LdT (n Z 104), or TDF (n Z 83) were enrolled.
The baseline characteristics are shown in Table 1. Patients
in the TDF group were younger and had a higher platelet
count compared with those in the ETV and LdT groups. The
mean HBV DNA was lower in the LdT group than in the ETV59) Telbivudine (n Z 104) Tenofovir (n Z 83) p
59.9  11.8b 54.9  10.9a,b 0.008
79 (76) 64 (77) 0.505
25.0  4.3 25.1  3.3 0.960
28 (27) 14 (17) 0.172
17 (16) 9 (11) 0.231
26 (25) 22 (27) 0.612
6 (6) 6 (7) 0.911
1041  429 720  315 0.707
5 (5) 6 (7) 0.422
6.0  1.4b,c 6.4  1.2b 0.039
61/31b 38/43b 0.032
2019  2272 2519  3570 0.673
15 (14) 19 (23) 0.562
71  89 90  140 0.233
83  107 123  211 0.220
14 (13) 8 (10) 0.265
1.5  2.4 1.5  2.8 0.499
3.7  0.5b 4.0  0.5a,b 0.016
1.0  0.5 1.0  1.5 0.651
39/38/11/2 41/33/2/1 0.433
86  30 92  23 0.259
21  68b 70  306a,b 0.059
127  59b 151  55a,b 0.012
9.1  3.3 8.4  3.0a 0.063
13 (13) 4 (5) 0.199
10 (10%)b,c 1 (1%)b 0.007
39.9  11.8b,c 20.3  6.4a,b <0.001
e; CKD Z chronic kidney disease; DDD Z defined daily doses;
HBsAg Z hepatitis B surface antigen; HBV Z hepatitis B virus;
nal disease (mL/min/1.73 m2); MELD Z model for end-stage liver
D post hoc correction or chi-squared test.
es of hepatitis B virus-related cirrhosis treated with nucleos(t)ide
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Figure 1 Cumulative incidences of HCC stratified by risk factors at baseline: (A) age, (B) statin, (C) ChildePugh classification, (D)
platelet count, (E) variceal bleeding history, and (F) NUCs. EVBZ esophageal variceal bleeding; HCCZ hepatocellular carcinoma;
NUC Z nucleos(t)ide analog.
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group was shorter than that in the ETV and LdT groups,
since TDF became available only 3 years ago in Taiwan.
Of them, 34 (6.2%) patients had received statin therapy
for more than 3 months during the observation period,
including simvastatin (n Z 4), rosuvastatin (n Z 10), pit-
avastatin (n Z 2), fluvastatin (n Z 6), and atorvastatin
(n Z 12). The comparison between statin users and non-
users is shown in Table S1.Treatment response
The numbers of patients with undetectable HBV DNA in the
ETV, LdT, and TDF groups were 268 of 311 (86%), 79 of 97
(81%), and 65 of 79 (82%) at Year 1 (pZ 0.436), and 205 of
221 (93%), 56 of 77 (73%), and 23 of 23 (100%) at Year 2
(p < 0.001), respectively. Treatment schedule was modi-
fied in 49 patients due to viral breakthrough (n Z 20),
suboptimal response (n Z 18), or side effect (n Z 11).
Viral breakthrough and genotypic resistance were found in
16 (15%) LdT-treated and four (1%) ETV-treated patients.
None of the patients changed NUC because of renal
dysfunction.
As shown in Figure S1, patients with statin use had a
lower rate of undetectable HBV DNA at Week 24 than
nonstatin users (50% vs. 71%, p Z 0.041). There were no
significant differences at Years 1, 2, and 3 between theseTable 2 Univariate and multivariate Cox regression analyses of
Comparison
Ha
Age (y) 60 vs. <60 1.7
Sex Male vs. female 1.1
Body mass index Per 1 kg/m2 increase 1.0
Diabetes mellitus Yes vs. no 1.3
Metformin vs. no 1.0
Hypertension Yes vs. no 1.7
Statin use Yes vs. no 3.0
Antiplatelet agent use Yes vs. no 1.7
Antiviral drug Telbivudine vs. entecavir 0.6
Tenofovir vs. entecavir 0.5
Baseline HBV-DNA Per log10 copies/mL increase 1.0
HBV DNA undetectable Year 1 Yes vs. no 0.6
HBV DNA undetectable Year 2 Yes vs. no 0.7
HBV genotype B vs. C 0.7
HBsAg titer Per 1 IU/mL increase 1.0
HBeAg positive Yes vs. no 1.4
ChildePugh class B or C vs. A 2.1
Ascites Yes vs. no 3.0
Total bilirubin Per 1 mg/dL increase 0.9
Albumin Per 1 g/dL increase 0.5
Creatinine Per 1 mg/dL increase 1.0
MELD score Per 1 increase 1.0
Alpha-fetoprotein Per 1 ng/mL increase 1.0
Platelet (103/mL) <100 vs. 100 1.8
Variceal bleeding history Yes vs. no 7.4
CI Z confidence interval; HBeAg Z hepatitis B e antigen; HBsA
HCC Z hepatocellular carcinoma; MELD Z model for end-stage liver
Please cite this article in press as: Tsai M-C, et al., Long-term outcom
analogs, Journal of the Formosan Medical Association (2016), http://dtwo groups but the rates appeared to be lower in statin
users. Patients with statin use also demonstrated a lower
trend of normalization rate of alanine transaminase,
although no significance was found at any time point.Factors associated with HCC development
A total of 56 patients developed HCC after a mean follow-
up period of 39.5  17.8 months. As shown in Figure 1, the
KaplaneMeier method showed that old age (60 years) at
entry (p Z 0.043), statin use (p Z 0.002), Child B/C
cirrhosis (p Z 0.013), low platelet count (<105/mL)
(p Z 0.048), and a history of gastroesophageal variceal
bleeding (p < 0.001) were associated with HCC develop-
ment. By contrast, antiviral medication did not affect this
outcome. The cumulative DDD was not significantly
different between HCC and non-HCC cases (834  552 vs.
602  577, p Z 0.289). There were no significant differ-
ences in HCC occurrence between different statins.
Based on stepwise Cox proportional hazard analysis, old
age (60 years) [hazard ratio (HR), 1.74; 95% confidence
interval (CI), 1.01e2.99; p Z 0.046], statin use (HR, 2.42;
95% CI, 1.17e5.01; p Z 0.017), low platelet count (<105/
mL) (HR, 2.00; 95% CI, 1.04e3.88; p Z 0.039), and gastro-
esophageal variceal bleeding history (HR, 5.12; 95% CI,
2.62e10.01; p < 0.001) were independent risk factors for
HCC development (Table 2).factors associated with HCC development.
Univariate analyses Stepwise multivariate analyses
zard ratio (95% CI) p Hazard ratio (95% CI) p
3 (1.01e2.95) 0.046 1.74 (1.01e2.99) 0.046
1 (0.61e2.03) 0.738 d d
2 (0.95e1.10) 0.572 d d
9 (0.78e2.48) 0.272 d d
5 (0.48e2.32) 0.902 d d
0 (0.98e2.95) 0.061 d d
0 (1.45e6.12) 0.003 2.42 (1.17e5.01) 0.017
9 (0.65e4.97) 0.261 d d
8 (0.32e1.45) 0.315 d d
2 (0.12e2.22) 0.378 d d
0 (0.82e1.22) 0.996 d d
8 (0.33e1.41) 0.294 d d
4 (0.23e2.42) 0.620 d d
8 (0.44e1.41) 0.416 d d
0 (1.00e1.00) 0.438 d d
4 (0.81e2.57) 0.217 d d
0 (1.16e3.80) 0.014 d d
3 (1.65e5.56) <0.001 d d
8 (0.89e1.07) 0.607 d d
3 (0.32e0.89) 0.016 d d
1 (0.84e1.21) 0.915 d d
3 (0.96e1.09) 0.450 d d
0 (0.99e1.00) 0.874 d d
3 (1.08e3.10) 0.025 2.00 (1.04e3.88) 0.039
7 (3.93e14.20) <0.001 5.12 (2.62e10.01) <0.001
g Z hepatitis B surface antigen; HBV Z hepatitis B virus;
disease.
es of hepatitis B virus-related cirrhosis treated with nucleos(t)ide
x.doi.org/10.1016/j.jfma.2016.08.006
6 M.-C. Tsai et al.
+ MODELFactors associated with overall survival
A total of 14 patients died during the follow-up period; 10
(71%) of them suffered from liver-related death: seven died
of HCC and three of complications associated with cirrhosis.
Of the four patients with non-liver-related death, two died
of malignancies other than HCC, one of acute stroke, and
one of an unknown cause.
As shown in Figure 2, the KaplaneMeier method showed
that Child B/C cirrhosis (pZ 0.001) and low platelet count
(<105/mL) (pZ 0.013) were associated with overall survival.
Univariate analyses showed that Child B/C cirrhosis
(pZ 0.002), ascites (pZ 0.001), albumin level (pZ 0.006),
model for end-stage liver disease score ({10 * [(0.957 * ln
(creatinine)] þ [0.378 * ln (bilirubin)] þ [1.12 * ln
(INR)]}þ 6.43) (pZ 0.002), and lowplatelet count (<105/mL)
(p Z 0.016) were significant factors for overall survival. By
the stepwise Cox proportional hazard model, Child B/CFigure 2 Overall survival stratified by risk factors at baseline: (A
and (D) NUCs. MELD Z model for end-stage liver disease; NUC Z
Please cite this article in press as: Tsai M-C, et al., Long-term outcom
analogs, Journal of the Formosan Medical Association (2016), http://dcirrhosis (HR, 3.78; 95% CI, 1.32e10.84, pZ 0.013) and low
platelet count (<105/mL; HR, 7.82; 95% CI, 1.01e60.41,
pZ 0.049) were independent factors (Table 3).Factors predicting progression of CKD stage
The progression of CKD stage was recorded from baseline to
follow-up. After excluding 11 patients (9 with end-stage
renal disease and 2 with CKD Stage IV), univariate analyses
showed that hypertension (pZ 0.002), TDF use (p < 0.001),
and pretreatment CKD Stage I (p < 0.001) were significant
factors associated with the progression of CKD stage. Based
on stepwise logistic regression analyses, hypertension (HR,
2.58; 95% CI, 1.65e4.04, p < 0.001), TDF use (HR, 1.98; 95%
CI, 1.23e3.21, p Z 0.005), and pretreatment CKD Stage I
(HR, 6.45; 95% CI, 0.71e11.19, p < 0.001) were indepen-
dent predictors (Table 4).) ChildePugh classification, (B) platelet count, (C) MELD score,
nucleos(t)ide analog.
es of hepatitis B virus-related cirrhosis treated with nucleos(t)ide
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Table 3 Univariate and multivariate Cox regression analyses of factors associated with overall survival.
Comparison Univariate analyses Stepwise multivariate analyses
Hazard ratio (95% CI) p Hazard ratio (95% CI) p
Age (y) 60 vs. <60 1.87 (0.63e5.58) 0.263 d d
Sex Male vs. female 1.37 (0.38e4.90) 0.631 d d
Body mass index Per 1 kg/m2 increase 1.02 (0.89e1.18) 0.789 d d
Diabetes mellitus Yes vs. no 0.59 (0.13e2.64) 0.489 d d
Hypertension Yes vs. no 0.52 (0.12e2.34) 0.396 d d
Statin use Yes vs. no 0.05 (0.00e622.5) 0.524 d d
Antiplatelet agent use Yes vs. no 0.05 (0.00e3997) 0.597 d d
Antiviral drug Telbivudine vs. entecavir 1.09 (0.30e3.96) 0.893 d d
Tenofovir vs. entecavir 0.04 (0.00e128037) 0.675 d d
Baseline HBV DNA Per log10 copies/mL increase 1.16 (0.77e1.76) 0.470 d d
HBV genotype B vs. C 2.93 (0.61e14.13) 0.180 d d
HBsAg titer Per 1 IU/mL increase 1.00 (0.99e1.00) 0.380 d d
HBeAg positive Yes vs. no 0.56 (0.13e2.52) 0.452 d d
ChildePugh class B or C vs. A 5.12 (1.79e14.62) 0.002 3.78 (1.32e10.84) 0.013
Ascites Yes vs. no 5.80 (2.01e16.77) 0.001 d d
Total bilirubin Per 1 mg/dL increase 1.06 (0.99e1.13) 0.078 d d
Albumin Per 1 g/dL increase 0.30 (0.12e0.71) 0.006 d d
Creatinine Per 1 mg/dL increase 1.01 (0.84e1.21) 0.915 d d
MELD score Per 1 increase 1.14 (1.05e1.23) 0.002 d d
Alpha-fetoprotein Per 1 ng/mL increase 1.00 (0.99e1.00) 0.283
Platelet (103/mL) 100 vs. <100 3.82 (1.28e11.42) 0.016 7.82 (1.01e60.41) 0.049
Variceal bleeding history Yes vs. no 3.00 (0.67e13.42) 0.151 d d
CIZ confidence interval; HBeAgZ hepatitis B e antigen; HBsAgZ hepatitis B surface antigen; HBVZ hepatitis B virus; MELDZ model
for end-stage liver disease.
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in mean estimated GFR between baseline and Years 1, 2, 3,
and 4 among patients treated with ETV. By contrast, esti-
mated GFR significantly increased in patients receiving LdT
at Year 1 (pZ 0.045) and Year 2 (pZ 0.047), but decreased
in those receiving TDF at Year 1 (p < 0.001) and Year 2
(p < 0.001) compared with baseline.Discussion
This large cohort study indicated that long-term NUC
therapy does not guarantee against the development of
HCC and mortality in CHB-related cirrhotic patients. Age,
statin use, platelet count, and variceal bleeding history
were independent risk factors for HCC development. In
addition, ChildePugh B/C and platelet count were inde-
pendent factors for overall survival. Our data were similar
to those in a previous report showing that the annual inci-
dence of HCC was 3.9% in LAM-treated HBV patients with
cirrhosis or advanced fibrosis.7 Another large multicenter
study in Caucasian patients showed 3.5% and 7.3% of annual
HCC rates, respectively, for patients with compensated and
decompensated cirrhosis.24 Taken together, it is obvious
that hepatocarcinogenesis in cirrhotic patients persists
even after long-term NUC therapy. However, although our
study was not a prospective randomized control trial, the
annual incidence of HCC in our treated patients appeared
to be lower than that in the untreated controls, based on
historical data (7.4e22.4%).7,8,10,24
In analysis for HCC development, our findings confirmed
that old age, low platelet counts, and a history of varicealPlease cite this article in press as: Tsai M-C, et al., Long-term outcom
analogs, Journal of the Formosan Medical Association (2016), http://dbleeding represented the major risk factors. These results
were consistent with those of previous reports.24e30 Not
only in natural history, but also in the treatment of CHB
patients, old age is absolutely the independent risk factor
for HCC development. In particular, baseline platelet count
is an independent factor predicting both HCC development
and overall survival, suggesting that platelet count may be
a useful surrogate marker for the severity of cirrhosis in
CHB.28 Previous studies have shown that patients with a
history of gastroesophageal variceal bleeding had a high
risk of developing HCC in long-term follow-up. Importantly,
this association is independent of the degree of liver
dysfunction and the duration of liver disease.29,30
Another intriguing finding is that statin use is an inde-
pendent risk factor for HCC development in our CHB-
related cirrhotic patients. Statins, 3-hydroxy-
3methylglutaryl-coenzyme A (HMG-CoA) reductase
inhibitors, a class of cholesterol-lowering drugs, are the
second most prescribed therapeutic medication following
painkillers.31 Long-term use of statin drugs has been shown
to increase risk of breast,32 thyroid,33 and prostate can-
cer,34 whereas many studies have reported the inverse as-
sociation between statin use and cancer risk.35e37 As
regards HCC, recent observational studies have demon-
strated that statin use may be associated with a lower risk
of HCC,37,38 although others have shown no association.39
However, these population-based studies were built on
health insurance research database plus medical diagnosed
codes,37,38 thus there was no detailed clinical information
such as virological data and cirrhosis. In contrast, our study
group consisted of CHB patients with cirrhosis who received
long-term NUC treatment and regular follow-up. Afteres of hepatitis B virus-related cirrhosis treated with nucleos(t)ide
x.doi.org/10.1016/j.jfma.2016.08.006
Table 4 Univariate and multivariate Cox regression analyses of factors associated with progression of CKD stage.a
Comparison Univariate analyses Stepwise multivariate analyses
Hazard ratio (95% CI) p Hazard ratio (95% CI) p
Age (y) 60 vs. <60 1.09 (0.62e1.92) 0.770 d d
Sex Male vs. female 0.73 (0.47e1.12) 0.149 d d
Body mass index Per 1 kg/m2 increase 1.02 (0.97e1.08) 0.444 d d
Diabetes mellitus Yes vs. no 1.08 (0.66e1.76) 0.775 d d
Hypertension Yes vs. no 1.93 (1.26e2.95) 0.002 2.58 (1.65e4.04) <0.001
Antiviral drug Tenofovir vs. nontenofovir 2.42 (1.51e3.89) <0.001 1.98 (1.23e3.21) 0.005
Baseline HBV DNA Per log10 copies/mL increase 1.16 (0.99e1.35) 0.069 d d
HBeAg positive Yes vs. no 0.95 (0.57e1.57) 0.840 d d
HBV genotype B vs. C 0.80 (0.52e1.23) 0.306 d d
HBsAg titer Per 1 IU/mL increase 1.00 (1.00e1.00) 0.786 d d
ChildePugh class B or C vs. A 1.32 (0.78e2.23) 0.305 d d
Ascites Yes vs. no 1.01 (0.51e2.00) 0.983 d d
CKD stage I vs. II/III 5.68 (3.30e9.79) <0.001 6.45 (3.71e11.19) <0.001
MELD score Per 1 increase 1.02 (0.966e1.08) 0.498 d d
Platelet (103/mL) 100 vs. <100 0.92 (0.55e1.55) 0.754 d d
Variceal bleeding history Yes vs. no 1.45 (0.63e3.31) 0.381 d d
CI Z confidence interval; CKD Z chronic kidney disease; HBeAg Z hepatitis B e antigen; HBsAg Z hepatitis B surface antigen;
HBV Z hepatitis B virus; MELD Z model for end-stage liver disease.
a Progression of CKD stage was defined as an increase of at least one stage in the follow-up.
Figure 3 Comparison of the eGFR change among entecavir,
telbivudine and tenofovir groups [telbivudine group: increased
at Year 1 (pZ 0.045) and Year 2 (pZ 0.047); tenofovir group:
decreased at Year 1 (p < 0.001) and Year 2 (p < 0.001)
compared with baseline]. eGFR Z estimated glomerular
filtration rate; MDRD Z modification of diet in renal disease
(mL/min/1.73 m2).
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+ MODELadjusting possible confounding factors including age and
diabetes mellitus (statin users were older and had a higher
rate of diabetes mellitus, as shown in Table S1), statin use
is an independent risk factor associated with HCC devel-
opment. However, we could not exclude the possibility that
statin users had a higher percentage of metabolic syn-
drome, which contributes to HCC development and pro-
gression since features of metabolic syndrome were not
completely collected in our study. Although the number of
statin users appeared to be relatively small, the prevalence
of statin use in HBV patients was comparable with that in a
prior population study.38 The reasons why statin use may
increase HCC risk in CHB-related cirrhotic patients treatedPlease cite this article in press as: Tsai M-C, et al., Long-term outcom
analogs, Journal of the Formosan Medical Association (2016), http://dwith NUCs remain unknown. One postulated mechanism is
that statins possibly affect antiviral effect by NUCs since
statins undergo first-pass hepatic metabolism, generally
through the cytochrome P450 system. The poor virological
response to antivirals has been reported to be associated
with an increased risk of clinical events and HCC in NUC-
treated patients.39 Further studies with more evidence
are necessary to support this finding.
Conversely, renal function has recently become a serious
concern in CHB treatment because TDF can lead to renal
toxicity, particularly at a high dose.40 In contrast, LdT has
been shown to improve renal function under unknown
mechanisms.41e43 Accordingly, it is interesting to investi-
gate the renal function change in CHB treatment, espe-
cially in cirrhotic patients, since life-long NUCs therapy is
necessary, and it is possible to receive liver transplantation
once the liver condition progresses. In our study, the fac-
tors associated with the progression of CKD stage were
hypertension, TDF use, and pretreatment CKD Stage I. The
estimated GFR was steadily increasing in the LdT group and
was stable in the ETV group after 4 years of treatment. In
contrast, the TDF group showed a significant decrease of
estimated GFR after 12 months and 24 months of treat-
ment. Taken together, these evidences suggested that TDF
should be used carefully in CHB-related cirrhotic patients,
and close monitoring of renal function test should be
necessary.
There are some limitations to our study. First, this is not
a truly prospective study. However, we believed that the
bias was small because patients were followed with clinical
and laboratory assessments, and HCC screening using serum
alpha-fetoprotein and ultrasonography every 3 months.
Second, the cohort of patients was enrolled in an Asian
population, with a low prevalence of statin use. Whether
statin has a similar impact on the NUC therapy in CHB-
related cirrhotic patients in areas with a high prevalence ofes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide
x.doi.org/10.1016/j.jfma.2016.08.006
NUCs for HBV cirrhosis 9
+ MODELhyperlipidemia and statin use remains to be clarified.
Third, the median follow-up time of TDF-treated patients
was relatively short, since this drug became available only
3 years ago in Taiwan. A longer follow-up period in the TDF
group should be needed in the future.
In conclusion, CHB-related cirrhotic patients still have a
high risk of HCC despite long-term treatment with NUCs.
Statin use is associated with a significant increase in the risk
of HCC among these patients. Although considerable un-
certainty is involved in the carcinogenesis associated with
statins, our observation suggests that careful HCC surveil-
lance is necessary in patients with old age, statin use, low
platelet count, and variceal bleeding history.Acknowledgments
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